Cranberry for the Prevention of Urinary Tract Infections

A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02454309

Enrollment

150

Registered

2015-05-27

Start date

2015-07-31

Completion date

2017-03-31

Last updated

2016-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infection

Brief summary

This study aims to determine whether a cranberry concentrate reduces recurrent urinary tract infections (UTIs) in women. Approximately 150 adult women will be recruited to participate in this study. Subjects will be randomized to either the cranberry supplement or placebo treatment for 12 months. Subjects and investigators will be blinded to which supplement they are taking.

Detailed description

Participants will be randomized to receive either a cranberry concentrate or placebo. Participants, study staff and investigators will remain blinded until after the dataset has been cleaned. At the baseline visit participants will be instructed to consume the assigned supplement twice daily for 12 consecutive months. A calendar will be provided to record compliance, recurrent UTIs and any side effects. Participants will be phoned/texted each month to encourage participation. Additional study visits will be completed at 3 months, 6 months and 9 months to collect information on recurrent UTIs and adherence. A urine sample will be collected from participants at each visit to test for pregnancy and the presence of an undetected UTI. Supplements will be distributed at each visit for the following 3-month study period and the last bottle of unused product returned. At the 12-month visit, participants will complete an end-line questionnaire and return their supplement bottle in addition to the calendar and side effect diary. If participants withdraw from the study, they will be encouraged to return at 12 months to complete a survey to allow for intent-to-treat analysis.

Interventions

DIETARY_SUPPLEMENTCranberry concentrate

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Females who have had at least 2 clinical-diagnosed symptomatic UTIs in the year preceding * Can communicate in English

Exclusion criteria

* Current UTI * Pregnant or breastfeeding or planning a pregnancy in the next 12 months * known allergy or intolerance to cranberry-containing products * A history of renal stones and/or renal transplantation * Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes * Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement * Intermittent or indwelling catheterization * Any anatomic abnormalities of the urinary tract * The use of any antibiotics within 2 weeks before study entry * The use of any natural health products, including herbs, homeopathic products, or other forms of cranberry supplements within 2 weeks before study entry

Design outcomes

Primary

Measure	Time frame
Number of urinary tract infections	12 months

Countries

Canada

Contacts

Primary ContactSarah J Harvey, MSc

sarah.harvey@ubc.ca6047542245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026